Comparison of 18FDG-PET/CT and conventional follow-up methods in colorectal cancer: A randomised prospective study
- PMID: 33153929
- DOI: 10.1016/j.dld.2020.10.012
Comparison of 18FDG-PET/CT and conventional follow-up methods in colorectal cancer: A randomised prospective study
Abstract
Background: A surveillance program was performed in colorectal cancer (CRC) patients after surgery, to diagnose asymptomatic recurrence.
Aims: To assess whether 18-FDG positron emission tomography/CT (PET/CT) improved the detection of recurrence during a 3-year follow-up.
Methods: A multicentre, two-arm randomised prospective trial comparing different 36-month follow-up strategies. Complete colonoscopy was performed at baseline and after 3 years and clinical exams with imaging every 3 months. The conventional arm (A) received carcinoembryonic antigen, liver echography, and alternated between lung radiography and computed tomography (CT) scans. The experimental arm (B) received PET/CT.
Results: A total of 365 patients with colon (79.4%) or rectal cancer (20.6%), stages II (48.2%) or III (50.8%), were enroled in this study. At 36 months, intention-to-treat analysis revealed recurrence in 31 (17.2%) patients in arm A and 47 (25.4%) in arm B (p = 0.063). At 3 years, 7 of 31 relapses (22.5%) in arm A were surgically treated with curative intent, compared to 17 of 47 (36.2%) in arm B (p = 0.25). The rates of recurrence and new cancers were higher in arm B than arm A (p = 0.038).
Conclusions: PET/CT follow-up every 6 months did not increase the rate of recurrence at 3 years or the rate of surgically treated recurrence compared with conventional follow-up.
Trial registration: ClinicalTrials.gov NCT00199654.
Keywords: 18FDG-PET/CT; Colorectal cancer; Follow-up study.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging.Oncologist. 2016 Dec;21(12):1502-1508. doi: 10.1634/theoncologist.2016-0222. Epub 2016 Oct 14. Oncologist. 2016. PMID: 27742904 Free PMC article.
-
Carcinoembryonic antigen directed PET-CECT scanning for postoperative surveillance of colorectal cancer.Colorectal Dis. 2017 Oct;19(10):907-911. doi: 10.1111/codi.13695. Colorectal Dis. 2017. PMID: 28444968
-
Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial.Ann Oncol. 2018 Apr 1;29(4):931-937. doi: 10.1093/annonc/mdy031. Ann Oncol. 2018. PMID: 29365058 Free PMC article. Clinical Trial.
-
[Positron emission tomography/computed tomography in follow-up programmes for patients with colorectal cancer].Ugeskr Laeger. 2016 Sep 12;178(37):V03160229. Ugeskr Laeger. 2016. PMID: 27649583 Review. Danish.
-
[Importance of FDG-PET/computed tomography in colorectal cancer].Radiologe. 2019 Sep;59(9):812-819. doi: 10.1007/s00117-019-00584-2. Radiologe. 2019. PMID: 31428810 Review. German.
Cited by
-
Clinical impact of PET/MRI in oligometastatic colorectal cancer.Br J Cancer. 2021 Sep;125(7):975-982. doi: 10.1038/s41416-021-01494-8. Epub 2021 Jul 19. Br J Cancer. 2021. PMID: 34282295 Free PMC article.
-
Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers.Semin Nucl Med. 2021 Sep;51(5):485-501. doi: 10.1053/j.semnuclmed.2021.04.001. Epub 2021 May 6. Semin Nucl Med. 2021. PMID: 33965198 Free PMC article. Review.
-
Tumor abnormal protein as a promising biomarker for screening solid malignancies and monitoring recurrence and metastasis.Front Oncol. 2023 Dec 5;13:1290791. doi: 10.3389/fonc.2023.1290791. eCollection 2023. Front Oncol. 2023. PMID: 38115905 Free PMC article.
-
Intensive follow-up vs conventional follow-up for patients with non-metastatic colorectal cancer treated with curative intent: A meta-analysis.World J Gastrointest Oncol. 2023 Dec 15;15(12):2197-2211. doi: 10.4251/wjgo.v15.i12.2197. World J Gastrointest Oncol. 2023. PMID: 38173431 Free PMC article.
-
Predictive value of intratumoral-metabolic heterogeneity derived from 18F-FDG PET/CT in distinguishing microsatellite instability status of colorectal carcinoma.Front Oncol. 2023 Apr 27;13:1065744. doi: 10.3389/fonc.2023.1065744. eCollection 2023. Front Oncol. 2023. PMID: 37182124 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical